Stocks
Rejected in February, refiling in December — the molecule is the same one
Disc Medicine said on Monday morning that its Phase 3 trial in erythropoietic protoporphyria had met every primary and secondary endpoint. Patients taking bitopertin gained 12.2 more hours a month in sunlight without pain than patients on placebo. The same morning, the company said it would sell $350 million in stock and pre-funded warrants.
Neither the drug nor the application is new. The FDA rejected this one in February.
Read what the rejection said. The agency agreed the earlier trials showed bitopertin lowers metal-free PPIX, the compound that makes daylight burn these patients. It said those trials never showed that lowering PPIX bought anyone time outdoors. A resubmission would need an adequate and well-controlled study using clinical endpoints.
EPP has one approved therapy, an implant. Bitopertin held one of the first of the FDA's new national priority vouchers, granted in October last year, which promised review in a month or two. That fast review ended in a rejection. What worked was running a trial that counted hours.
So Monday was not news about a medicine. The molecule, the dose and the mechanism are what they were a year ago. What changed is the kind of evidence attached to them. Disc refiles by the end of December and expects a decision by mid-2027.
Biotech tickers crowd the board here this week. Few of them are waiting on a discovery.
When a regulator turns something down where you trade, is the reasoning published — or do you learn only that the answer was no?
0
Comments 0